BiotechTube

simvastatin + Ezetimibe

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Jul 1, 2006 → —

NCT ID
NCT00753883

About simvastatin + Ezetimibe

simvastatin + Ezetimibe is a approved stage product being developed by Merck for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00753883. Target conditions include Hyperlipidemia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT00753883ApprovedCompleted
NCT00466401ApprovedCompleted

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
VK2809 + PlaceboViking TherapeuticsPhase 2
47
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
77
Diet+pravastatinDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
85
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
77
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
77
exenatideEli LillyPre-clinical
23
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
33
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
33
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
41
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
52
Rosuvastatin (Crestor)AstraZenecaApproved
85
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
77
simvastatin 20 mg/ezetimibeMerckPhase 2/3
65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
77
Sitagliptin + PlaceboMerckPhase 2/3
65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)NovartisPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85